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ABSTRACT
Objective To systemically review the evidence from
clinical trials comparing the use of crystalloids and
colloids for fluid resuscitation in children with severe
infection.
Data sourcesMedline (1950-2008), PubMed, the
Cochrane Library, Embase (1980-2008), and reference
lists.
Eligibility criteria Published studies comparing fluid
resuscitation with crystalloid or colloidal solutions in
severe infectious illness in children aged >1 month to ≤
12 years. Controlled trials and randomised controlled
trials were separately selected by two unblinded
investigators who also independently extracted data.
Main outcome measures Efficacy in the treatment of
shock, mortality, and reported adverse events.
Results Nine trials fulfilled criteria, eight of which
compared crystalloids with colloids. All trials were
conducted in settings with poor resources and
predominantly included patients with malaria or dengue
haemorrhagic shock. None of the trials had mortality as a
primary outcome. Three out of six studies that reported at
least one death showed better survival in children
resuscitated with colloids compared with crystalloids
(Peto fixed odds ratio ranging from 0.18 (95% confidence
interval 0.02 to 1.42) to 0.48 (0.06 to 3.99)). Studies
contributing data on mortality had some methodological
limitations so caution is recommended when interpreting
this finding. Studies were heterogeneous so combined
estimates were not calculated. The review was limited by
inclusion of only published studies.
Conclusions The current evidence on choice of fluids for
resuscitation in children with infections is weak. While
existing trials have provided important evidence in
malaria and dengue, resuscitation in children with
paediatric sepsis, for which colloids could theoretically
be of benefit, has not been studied. The evidence from
existing studies is not robust enough to make any
definitive recommendations over the choice of
resuscitation fluid and a definitive trial is required to
address this.
INTRODUCTION
Circulatory shock is a major cause of morbidity and
mortality among children requiring emergency care.1
The leading cause of circulatory failure in children is
hypovolaemia, usually secondary to severe infection.2
Early and rapid fluid resuscitation with isotonic solu-
tions is the cornerstone of management. For children,
however, there is still no clear consensus over the
choice of resuscitation fluid, and colloidal solutions
(such as human albumin solution) might be better
than the cheaper crystalloids (such as normal
saline).3-11 Although physiological explanations have
been advanced to support potential benefits of colloids
over crystalloids, the current evidence does not sup-
port these.3-5 Earlier Cochrane meta-analyses con-
cluded that human albumin solution resulted in
increased mortality,3 5 6 but these conclusions were dis-
puted and a subsequent meta-analysis showed that use
of human albumin solution or 0.9% saline resulted in
similar survival.4 This conclusion was greatly influ-
enced by the results of a trial of human albumin solu-
tion compared with saline in 7000 adults in Australia
and New Zealand (SAFE study), which reported simi-
lar survival in both treatment arms.12 A non-significant
trend towards improved survival was noted in the sub-
group of patients with sepsis treated with human albu-
min solution. Successive meta-analyses, however,
have consistently found that crystalloids are preferable
to colloids in patientswithburns, trauma, surgery, trau-
matic head injury, and gastroenteritis.3-7 9 12 Although
the debate in adults is far from over, there is also con-
siderable uncertainty in themanagement and choice of
fluids in paediatric shock.
Conclusions drawn from trials in adults cannot sim-
ply be extrapolated to children for several reasons.
Firstly, children have a different physiological
response to severe illness. The development of low car-
diac index and high systemic vascular resistance is
common in community acquired septic shock (cold
shock), whereas in adults, low cardiac index and low
vascular resistance (warm shock) is common.13 Sec-
ondly, children have a larger ratio of surface area to
volume and therefore lose more fluid than adults and
also often respondwell to aggressive volume resuscita-
tion as they tolerate larger fluid volumes per kilogram
of body weight.14 Finally, children are at increased risk
of meningoencephalitis, and, as the presentation of
paediatric shock often includes a degree of impaired
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consciousness, this possibility cannot be excluded in
fluid resuscitation guidelines. In this circumstance,
there is a notional possibility that resuscitation with
colloidal solutions could be a safer option than crystal-
loid solutions, which might increase the risk of exacer-
bating brain swelling or increases in intracranial
pressure. For these and several other reasons separate
paediatric guidelines have been developed for the
emergency assessment and treatment of children.15-17
Current paediatric practice, however, continues to be
influenced by the first Cochrane meta-analysis. A sur-
vey conducted after the publication of an earlier meta-
analysis, which reported an increased risk of mortality
in patients resuscitated with human albumin solution,
showed a marked decline in the use of albumin in pae-
diatric intensive care units in theUK.18 The survey also
highlighted the widespread lack of written guidelines
for fluidmanagement. For low income countries, inter-
national guidelines follow those developed by the
World Health Organization, which currently recom-
mends different fluids and volumes for treating shock
depending on the underlying disease condition.17 19 20
We summarised the evidence available from trials
dealing with management of shock in children with
severe infection. We included sepsis and sepsis-like
conditions, for which there are equipoise or theoretical
advantages for using colloids. We excluded studies in
children with burns, trauma, surgical conditions, and
gastroenteritis as there is substantial agreement that
crystalloids are preferable.3-7 9 12 To avoid heterogene-
ity in populations of patients, a criticism of previous
meta-analyses,21 we also excluded studies in neonates
because of differences in presentation of clinical dis-
ease and host physiology.
METHODS
Information sources—We searched Medline (1950 to
September 2008), Embase (1980 to September 2008),
Pubmed, and the Cochrane library. Reference lists for
the initial studies retrieved were examined to identify
any additional relevant studies missed by the electro-
nic searches. We also reviewed the studies reported in
the previous Cochrane meta-analyses.
Search strategy—There were no language restrictions
but we limited searches to children aged 1 month to
12years.Weexcluded studies that reported fluid resus-
citation restricted to diarrhoea, trauma, and surgery.
Our strategy was developed by breaking the review
question into exposure, intervention, population, pub-
lication language, and key words as recommended by
theNationalHealth Service (NHS)Centre forReviews
and Dissemination.22 Highly sensitive Medline search
filters were also used.23 Only published studies avail-
able up to September 2008 were included, and we did
not contact authors of the relevant studies for any
unpublished work. Details of the search strategy are
in appendix 1 on bmj.com.
Study selection—Titles and abstracts of all the studies
retrieved were reviewed to identify relevant studies for
inclusion. We obtained and assessed full transcripts of
potentially relevant studies to ascertain whether they
met the inclusion criteria. Disagreements were
resolved with the input of the third author.
Eligibility criteria—The studies were selected if they
were controlled trials, quasi-randomised trials, cohort
studies, and randomised controlled trials that compared
different intravenous fluids, given as boluses, for the
treatment of shock in children aged between 1 month
and 12 years. Included trials studied crystalloids versus
colloids, crystalloids versus crystalloids, or colloids ver-
sus colloids. We selected trials that investigated fluid
resuscitation in any infectious disease anywhere in the
world, including sepsis, malaria, dengue, and any other
infectious cause that could be traced. We excluded stu-
dies that reported fluid resuscitation in diarrhoeal dis-
ease, burns, and trauma or injury cases, andwhere fluid
was given for a surgical procedure or anaesthesia pur-
poses (see appendix 2 on bmj.com for details).
Data collection process—The two investigators indepen-
dently assessed the methodological quality of the
selected studies using a pre-developed proforma. Infor-
mation on study design, adequacy of randomisation,
degree of allocation concealment, blinding/masking,
and follow-up were assessed.When there was disagree-
ment, the opinion of the third author was sought.
Data items—Two unblinded investigators (SA and
HL) extracted the data, collecting information on cate-
gory of disease, authors, year of publication, country
where the study was conducted, study design (rando-
misation, allocation,masking), number of participants,
fluid interventions given, outcomemeasures used, side
effects of interventions, and mortality.
Synthesis of results—We report a qualitative descrip-
tion of studies when statistical pooling was not possible
and a quantitative summary when it was. Clinical and
methodological heterogeneities were assessed by
reviewing and comparing the patient populations,
interventions, outcomes, disease spectrum covered,
study design, and risk of bias. We used the RevMan
software to assess the risk of bias by reviewing the
methods used in the studies for adequacy of sequence
generation, allocation concealment, blinding, comple-
teness of the data, and selective reporting.24 25
Summary measures—For studies that compared crys-
talloids with colloids (any colloid or human albumin
solution alone) and reported at least one death (in
either arm), we calculated the Peto odds ratio using
the fixed effects model for each study, derived a forest
plot, and used a χ2 test for statistical heterogeneity. Stu-
dies judged to have clinical or methodological hetero-
geneity were not combined.
RESULTS
Study selection
We identified 1016 studies from our search, of which
120 studies were found to be relevant. Twenty one stu-
dies were selected from the relevant studies, full copies
retrieved, andmoredetailedmethodological evaluation
done. Only nine studies were finally identified as meet-
ing the inclusion criteria (fig 1), and 12 studies1226-36
were excluded at this stage (see appendix 2 on
bmj.com).
RESEARCH
page 2 of 8 BMJ | ONLINE FIRST | bmj.com
Study characteristics
The total number of patients reported in the studies
was 1198, with the largest study reporting 512 patients
and the smallest 27 (table). All nine studies were con-
ducted in low income settings, four in Kenya37-40 and
five in Asia.41-45 Four studies were in children with
malaria, four in those with dengue shock syndrome,
and one study in those with sepsis.
Risk of bias within studies
Two trials conducted in children with severe malaria
did not have adequate sequence generation, had no
allocation concealment, were open labelled, and were
quasi-randomised.37 40 Two other studies had adequate
sequence generation and allocation concealment but
were unblinded and had a similar follow-up to hospital
discharge. The three trials conducted in children with
dengue shock syndrome in Vietnam were all double
blind randomised trials with adequate allocation con-
cealment and adequate sequence generation.41-43 The
fourth trial in dengue patients was conducted in the
Philippines and reported that therewas systematic allo-
cation, though this was not described in detail. Follow-
up in the Philippines study was only for the duration of
stay in the intensive care unit, and all the children who
died were reported to have had a protocol violation.
The trial conducted in children with septic shock in
India was open labelled, had adequate randomisation
and adequate sequence generation, and the period of
follow-up was also described.
Study findings
Our main outcomes were efficacy in the treatment of
shock, mortality, and reported adverse events.
Treatment of shock
Most studies had resolution of shock and achievement
of haemodynamic stability as an outcome. Different
variables were used to define these, including the
volume of fluids needed for resuscitation, the time
taken for haemodynamic stabilisation, the need for
“rescue” fluids, acid-base normalisation and recovery,
duration of shock, and any subsequent episodes of
shock. Generally, there were no significant differences
in the recovery from shock in patients resuscitatedwith
various fluids compared in trials in sepsis or malaria.
The trials conducted in dengue shock reported a super-
ior efficacy of colloids over crystalloids for resolution
of severe shock, with faster restoration of cardiac index
and normalisation of packed cell volume or blood
pressure, or both.
In children with severe malaria, there were similar
improvements in central venous pressure with equiva-
lent volumes of either 0.9% saline or 4.5%human albu-
min solution.37 In other trials without invasive
monitoring, there were similar reductions in acidosis
and other features of shock3839 in children receiving
human albumin solution or saline and in those receiv-
ing albumin or Gelofusine (a gelatin based colloid).40
Three studies in children with dengue shock, con-
ducted by the same research group in Vietnam, applied
similar studymethods across all their trials. In the largest
of the three trials, the primary endpointwas the require-
ment for rescue by colloidal fluids at any time point.
Rescue colloid was given if there was narrowing on
response in pulse pressure accompanied with periph-
eral shutdown or rising packed cell volume, or both.43
The study also compared restoration of cardiac index,
normalisationof packed cell volume, andnormalisation
of blood pressure. For children with severe shock,
defined as pulse pressure ≤10mmHg, colloids resulted
in better resolution of severe shock quantified by the
secondary end points when comparedwithRingers lac-
tate. Inmoderate shock (pulse pressure>10mmHgbut
≤20 mm Hg), Ringers lactate had similar results to
colloids.43 The Philippines trial, which enrolled 27 chil-
dren with dengue shock and compared hydroxyethyl
starch (6% Haes-Steril) with Ringers lactate, reported
that the starch controlled shock for longer and resulted
in less need for other rescue treatment other than
Ringers lactate.
The study in paediatric sepsis involved 60 patients
and showed similar haemodynamic stability at 6 and
12 hours among those resuscitated with saline or gela-
tin polymer (Haemaccel).45 Haemodynamic variables
used to assess resolution of shock included heart rate,
capillary refill time, pulse volume, and blood pressure.
The authors noted that resuscitation with saline
required 20 ml/kg more than the volume of gelatin
polymer required to achieve haemodynamic stability,
measured by capillary wedge pressure.
Titles and abstracts identified and screened (n=1016)
Potentially relevant studies (n=120)
Studies retrieved for more detailed evaluation (n=21)
Excluded trials (not relevant) (n=896)
Excluded studies (n=99):
  Reviews (n=51)
  Surgery (n=15)
  Other trials (not resuscitation) (n=11)
  Adult trials (n=4)
  Case reports/series (n=4)
  Neonates (n=3)
  Burns (n=2)
  Renal (n=2)
  Comments or opinions (n=2)
  Observational studies (no comparison) (n=3)
  Physiological studies (n=1)
  Autologous blood donors (n=1)
Studies included in the review (n=9)
Excluded studies (n=12):
  Adult (n=4)
  Trauma (n=1)
  Diarrhoea (n=1)
  Albumin given to treat hypoalbuminaemia (n=1)
  Cancer (n=1)
  Allergic reaction (n=1)
  Other language (Japanese, Polish) (n=2)
  Yet to retrieve (n=1)
Fig 1 | Summary of trials on fluid resuscitation in children
retrieved from searches
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Characteristics of studies retrieved on paediatric fluid resuscitation
Study Methods Participants Interventions Outcomes Comments
Akech 200640 Controlled trial (quasi-
randomisation). Sequential blocks
of 10. No blinding. No allocation
concealment. Follow-up to
discharge fromhospital for adverse
events
88 children with
malariaage>3months
with metabolic
acidosis (base deficit
>8 mmol/l);
Hb >50 g/l; plus
clinical feature of
shock
Gelofusine (n=44); 4.5% HAS
(n-44). Admission: bolus 20 or
40 ml/kg (if hypotensive ). Further
20ml/kg if shock present at 1 hour
Resolution of shock. Resolution of
acidosis at 1 and 8 hours. In
hospital death. Adverse events.
Neurological sequelae. Allergic
reactions
Quasi-randomisation. Inadequate
allocation concealment.
Inadequate sequence generation.
Colloid v colloid comparison
Cifra 200344 Quasi-randomised trial. Patients
allocated “systematically.”
Alternate allocation. No
information on blinding. All
outcomes in hospital. No loss to
follow-up
Dengue shock
syndrome;
27 children
6% Hydroxyethyl starch (Haes-
Steril) (n=11); Ringers lactate
(n=16)
Duration of control of shock,
frequency of recurrence of shock,
length of ICU stay, mortality
Inadequate allocation
concealment. Inadequate
sequence generation
Dung 199941 RCT. Allocation concealment with
numbered opaque envelopes.
Double blind with opaque
envelopes in blocks of 10. Fluid
masked with black opaque
containers. Follow-up to hospital
discharge
Dengue shock
syndrome; 50
children aged
5-15 years who had
not received IV fluid
therapyduringcurrent
illness
Dextran 70 (n=12); 3% Gelafundin
(n=13); Ringers lactate (n=13);
normal saline (n=12). Bolus
20ml/kgover1hour,10ml/kgover
2nd hour
Recovery from shock (pulse
pressure≤20mmHg), durationand
No of episodes of shock,
improvements in cardiac output
and packed cell volume, and,
requirements for further fluid
resuscitation
Adequate allocation concealment
and adequate sequence
generation. No deaths
Maitland 200337 Controlled trial (quasi-
randomisation). Alternate
systematic allocation. Allocation
also based on availability of study
fluid. No blinding. No allocation
concealment.Follow-upto48hours
after admission for haemodynamic
variables and blood gases
(acidosis)
53 children with
severe malaria aged
6 months-12 years.
Metabolic acidosis
(base deficit
>8 mmol/l). Divided
into severe anaemia
(Hb <50 g/l) or no
severe anaemia
0.9% saline (n=20); 4.5% HAS
(n=32); saline and HAS (n=1).
Aliquots of 10 ml/kg given to
achieve CVP 5-8 cm H2O. Bolus of
10-40 ml/kg given over 1st hour
after admission
Resolution of acidosis/base deficit
reduction at 8 hours, CVP 5-8 cm
H2O and, improvement of
haemodynamic indices
Inadequate allocation
concealment and inadequate
sequence generation
Maitland 200538 RCT. No blinding. Allocation
concealment with opaque
envelopes. Follow-up to discharge
from hospital for adverse events
150 children with
severe malaria, age
6 months-12 years.
Metabolic acidosis
(base deficit
>8mmol/l), Hb >50 g/l
0.9% saline (n=61), 4.5% HAS
(n=56), no bolus (n=33). Moderate
acidosis (base deficit 8-15mmol/l):
received 20ml/kg (saline and HAS)
or no bolus (control). Severe
acidosis (base deficit >15 mmol/l)
received 40 ml/kg, no control
group. Rescue if hypotensive or
oliguria
Resolution of acidosis/base deficit
reduction at 8 hours, in-hospital
death,neurological sequelae, need
for rescue therapies
Adequate allocation concealment.
Computer generated
randomisation sequence
produced by an independent
statistician, information provided
by authors of review who
conducted studies
Maitland 200539 RCT. Allocation concealment with
sealed card system. No blinding.
Follow-up to discharge from
hospital for adverse events
61 children with
symptomatic severe
malaria anaemia, age
>2 months plus
metabolic acidosis
(base deficit
>8 mmol/l)
0.9% saline (n=20), 4.5% HAS
(n=23),orcontrol (nobolus) (n=18).
Bolus 20 ml/kg of normal saline or
albumin over 1 hour while awaiting
blood transfusion.
Resolution of acidosis/base deficit
reduction at 8 hours, in-hospital
death, neurological sequelae
Adequate allocation concealment.
Computer generated
randomisation sequence
produced by independent
statistician, information provided
by authors of review who
conducted studies
Ngo 200142 RCT. Double blind with fluid
masked using black opaque
containers. Allocation concealment
with opaque envelopes in blocks of
10. Follow-up to hospital discharge
230 children with
Dengue shock
syndrome, aged
5-15 years, had not
received IV fluid
therapyduringcurrent
illness
Dextran 70 (n=55), 3% gelatin
(Gelafundin) (n=56), Ringers
lactate (n=55), or normal saline
(n=56). Bolus20ml/kg over1 hour,
10 ml/kg over 2nd hour. 8 children
had dengue haemorrhagic fever
grade IV and not randomised
Recovery from shock (pulse
pressure≤20mmHg), durationand
No of episodes of shock,
improvements in cardiac output
and packed cell volumes,
requirements for further fluid
resuscitation
Adequate sequence generation
and adequate allocation
concealment. No deaths
Upadhyay
200545
RCT. Open label, randomised.
Random tables used to generate
numbers. Allocation concealment
with sealed envelopes and kept
with one investigator. Monitoring
till 6 hours after stability then till
recovery
60 children with
sepsis, age 1 month
-12 years. Septic
shock, without
clinical evidence of
organ failure at
admission or
hypotension
Normal saline (n=31) or,
Haemaccel (n=29). Bolus 20 ml/kg
of 0.9% saline or Haemaccel till
haemodynamically stable or if CVP
>10 mm Hg
Haemodynamic stabilisation (heart
rate, capillary refill time, pulse
volume, blood pressure in normal
range), plasma volume at end of
fluid resuscitation, incidence of
organ dysfunction
Adequate allocation concealment
and adequate sequence
generation
Wills 200543 RCT. Computer generated random
numbers. Double blind treatment
packs in sealed special cardboard
containers, identified only by study
number. Independent staff not
involved in care prepared packs
and randomisation. Pre-sealed and
pre-labelled envelopes used in
emergency. Allocation
concealment. Follow-up to
discharge from hospital
512 children with
clinical dengue shock
syndrome, aged
2-15 years
Ringers lactate (n=128), 6%
Detran70 (n=193), or 6%
hydroxyethyl starch (n=191).
Group 1=(moderate shock: pulse
pressure >10 and ≤20 mm Hg)
Dextran, starch, or Ringers lactate.
Group 2=(severe shock: pulse
pressure <10 mm Hg) allocated to
Dextran or starch and given
15ml/kgover1hour,10ml/kgover
2nd hour
Requirement for rescue colloid at
any time after infusion of study
fluid, time taken to achieve initial
cardiovascular stability (pulse
pressure ≥25 and systolic blood
pressure ≥ 80 mm Hg for minimum
of 2 hours), volumes of rescue
colloid and total parenteral fluid
required, No of days in hospital,
change in packed cell volume,
allergic reactions
Adequate sequence generation
and adequate allocation
concealment
RCT=randomised controlled trial; Hb=haemoglobin; HAS=human albumin solution; CVP=central venous pressure; ICU=intensive care unit.
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Other end points used in the studies to compare effi-
cacy of treatment of shock included use of secondary
resuscitation strategies and incidence of organ failure.
Mortality
None of the studies were designed or adequately pow-
ered to examine mortality as a primary outcome. The
four trials in dengue enrolled 819 children and reported
five deaths. Because of the expected low mortality in
dengue, this was not a stated end point. Therefore no
conclusions can be drawn about the survival benefit
between colloids and crystalloids in this disease.
A totalof 352childrenwereenrolled in fluidexpansion
trials in children with severe malaria. Two studies
included 51 children randomised to a “no bolus” (con-
trol) strategy.3839 One study that compared 0.9% saline
with human albumin solution showed a significant over-
all reduction inmortality in the albumin group (P=0.013)
and in the high risk subgroup, where acidosis and shock
was complicated by coma (P=0.002). There were, how-
ever, no differences between the fluid intervention arms
in cases without coma (P=0.7).38 The survival advantage
was also noted in the trial of human albumin solution
compared with Gelofusine (a gelatin polymer), in which
mortality was lower in the albumin group (P=0.06), par-
ticularly in the subgroup with coma (P=0.04).40
The trial conducted in children with sepsis found no
difference inmortality with fluids used: 9/31 (29%) sal-
ine recipients died compared with 9/29 (31%) in the
gelatin polymer group
Adverse events
There was a non-significant increase in neurological
sequelae with human albumin solution compared
with other fluids in children who survived severe
malaria: 9/136 (7%) with albumin, 2/95 (2%) with sal-
ine, and 1/37 (3%) withGelofusine.37-40 One episode of
allergic reaction was reported in a child receiving
Gelofusine.40 Pulmonary oedema, unrelated to the
intervention, was reported in two of 61 (3%) children
who received saline in one trial.38 In childrenwith den-
gue who received dextran, 15/193 (8%) developed
signs of severe reactions, which included fever and
rigors without cardiorespiratory compromise, while
one of 191 children who received starch (6% hydro-
xyethyl starch) developed an afebrile event with an
urticarial rash in the same trial.43 In another dengue
trial 5/56 (9%) children who received gelatin polymer
(Gelafundin) and one (1/70) who received dextran
developed allergic reactions but without signs of
cardiovascular compromise.42 One child who received
gelatin suffered severe epistaxis and required a blood
transfusion, and another who received dextran devel-
oped a haematoma at an injury site.42 The Indian trial
in children with sepsis reported no adverse reactions.45
Quantitative data synthesis
Colloids versus crystalloids
We selected six trials (three malaria trials, two dengue
trials, and one sepsis trial) that reported at least one
death to compare colloids and isotonic crystalloids (nor-
mal saline orRingers lactate).37-3943-45 These included811
participants, 523 randomised to colloids and 288 to crys-
talloids, and reported 48 deaths (17 in those receiving
colloids). Though the forest plots indicated no significant
heterogeneity (χ2=2.66, P=0.26), we chose not to provide
a composite estimate because of clinical heterogeneity in
the a priori risk of mortality between the different condi-
tions (dengue, severe malaria, and sepsis). Three out of
the six studies showed better survival in children resusci-
tated with colloids compared with crystalloids, but the
wide confidence intervals in these studies caution against
interpreting this as a true effect of treatment. Figure 2
summarises the results.
Albumin crystalloids
Because of the ongoing debate we examined the effect
of human albumin solution in resuscitation on
survival.5 7 11 46-48 The only trials included were those
in children with severe malaria (fig 3). We found
important clinical heterogeneity in these studies as
one enrolled children with severe anaemia, in whom
fluid resuscitation was given as pre-transfusion
management,39 while the two other studies excluded
children with severe malaria anaemia, 37 38 hence we
could not calculate combined summary estimates.
The largest of these trials showed a significant reduc-
tion in mortality for children resuscitated with human
albumin solution compared with saline38; another trial
showed non-significantly reduced mortality37; while
the third trial (in those with severe malaria anaemia)
showed no difference in survival. 38 Another trial in
children with severe malaria that compared human
albumin solution with Gelofusine reported a non-sig-
nificant reduction in mortality in those resuscitated
with human albumin solution.40 Mortality in the
human albumin solution armwas 1/44 (2%) compared
with 7/44 (16%) in the Gelofusine arm (Peto odds ratio
0.20, 95% confidence interval 0.05 to 0.83, P=0.03).
Sepsis
In the only trial included, therewas no difference in the
risk of mortality between saline and gelatin polymer
(Peto odds ratio 1.10, 0.37 to 3.29, P=0.87).45
Sepsis
  Upadhyaya 200545
Malaria
  Maitland 200538
  Maitland 200539
  Maitland 200337
Dengue
  Wills 200543
  Cifra 200344
1.1 (0.4 to 3.3)
0.23 (0.07 to 0.74)
1.2 (0.24 to 5.9)
0.18 (0.02 to 1.4)
3.8 (0.04 to 350)
0.48 (0.06 to 4.0)
9/29
2/56
4/23
0/20
1/384
1/11
0.01 0.1 1 10 100
Study or
subgroup
Favours
colloids
Favours
crystalloids
Peto fixed odds
ratio (95% CI)
Peto fixed odds
ratio (95% CI)Colloids
9/31
11/61
3/20
4/32
0/128
3/16
Crystalloids
Yes
Yes
Yes
No
Yes
No
Adequate
sequence
generation
Events/total
Fig 2 | Comparison of mortality in children resuscitated with colloids or crystalloids
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Risk of bias across studies
The studies conducted in Vietnamese children with
dengue had a low risk of bias but limited information
about mortality.41-43 Most information on the effect of
colloids on mortality came from studies in children
with severe malaria, which were unblinded and small
in size and two had quasi-randomisation—all factors
that increase risk of bias.37-40 The study in sepsis also
had high risk of bias because it was small in size and
had no sample size calculation. The study in dengue in
the Philippines had a high risk of bias because of the
study design.44
DISCUSSION
Summary of evidence
This review of fluid resuscitation in paediatric shock in
severe infection found few trials and showed that there
is insufficient evidence to support the preferential use
of colloids or crystalloids in paediatric sepsis. While
this finding is in agreement with meta-analyses in
adults, which found a similar survival benefit in resus-
citationwith either colloids or crystalloids, recommen-
dations in adults were informed bywell powered trials.
This contrasts with the evidence from paediatrics,
which can be drawn only from trials too small in size
to adequately inform a meta-analysis with respect to
the questions of survival, management guidelines, or
policy. The randomised trials in dengue septic shock
involved a large number of patients, but as mortality
was rare, these studies were also unsuitable to address
this particular question.
There is substantial evidence indicating that colloids
are better than crystalloids for treating severe shock in
dengue septic shock, but both have similar efficacy in
moderate shock. As severe shock in dengue septic
shock ismuch less common thanmoderate shock, crys-
talloids remain the mainstay for treatment of this
condition.41-43 49 In malaria, the analysis indicated a
superior survival benefit with human albumin solution
compared with either saline or another colloid (Gelo-
fusine), but the results were insufficient to inform pol-
icy because of the small sample size and some
limitations of the study design. The single trial in chil-
dren with sepsis was too small to detect differences in
mortality but showed that a larger volume of crystal-
loidwas required to achieve the same resuscitation end
point as colloid.
The apparent reduction inmortality in childrenwith
severe malaria who received human albumin solution
as fluid expansion is interesting but needs further clar-
ification. Small trials tend to overestimate the overall
effect.50 Together with some methodological aspects,
the interpretation of results from a single site can also
contribute to an overestimated effect of treatment.51-53
Nevertheless, the results merit confirmation in a defi-
nitive trial, and one is currently underway (www.feast-
trial.org).
This review brings into focus a few important issues.
Firstly, there are surprisingly few trials examining fluid
resuscitation strategies in children. Fluid resuscitation
is common in modern paediatrics, with recommenda-
tions based on consensus or expert opinion rather than
results of definitive studies or meta-analysis. Secondly,
as the studies were not designed with mortality as the
primary outcome and used different definitions of
resolution of shock as outcomes, it would bemethodo-
logically incorrect and misleading to combine the
results to obtain a summary estimate. Thirdly, of the
nine trials included, all were conducted in resource
poor countries, despite fluid resuscitation practice
being much less common.
International paediatric treatment guidelines, which
have been prospectively evaluated, indicate that
60 ml/kg of isotonic resuscitation fluid given in the
first hour of development of shock leads to a ninefold
reduction in mortality,54-56 and every hour that hypo-
volaemia is uncorrected results in doubling of
mortality.54 56 Currently there are no evidenced based
recommendations to guide the optimal choice of fluid
for resuscitation in these or other guidelines. Acute
bacterial infections, together with malaria in Africa
and dengue in South East Asia, are common causes
of hospital admission and are one of the commonest
infectious causes of death. Few children with sepsis
and severe malaria receive supportive treatments,
including fluid resuscitation, which is generally
reserved for children with advanced features of
shock.19 20 The trials included in this meta-analysis
were conducted mainly on hospital wards with limited
sophisticated life support equipment. They represent
proof of principle trials, aimed at generating important
data to guide the next stage (late phase clinical trials or
guideline development). The focus was on fluid
responsive rather than fluid refractory shock, and the
relevance of this meta-analysis to children requiring
inotropic support is uncertain.
The question of which fluid is ideal for resuscitation
remains unanswered and hence is pertinent
globally.4-7 10 57 Differences in physiological dysfunc-
tion, speed of the development of shock, complica-
tions, and case fatality before intervention frustrate
the development of a single fluid resuscitation strategy
appropriate for all contexts. Consequently, debate
over the merits of volume resuscitation with colloids
or crystalloids could have different relevance because
of the distinct pathophysiological mechanisms that are
involved in different underlying diseases in children.
For example, the tempo of dengue shock is generally
slow, with shock developing over many hours or days
because of haemoconcentration as a result of severe
  Maitland 200537
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Fig 3 | Comparison of mortality in children resuscitated with albumin or crystalloids
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capillary leak. This contrasts with shock in sepsis and
possibly malaria, which progresses rapidly with a high
risk of early mortality.58 In addition, for those with
impaired consciousness there is the potential risk of
brain swelling for sepsis andmalaria, whereas neurolo-
gical complications are rare in dengue shock.43
Our review points to an improved outcome for chil-
dren receiving colloids. Whether viewed as tantalising
or inconsequential evidence, it indicates that this
should be evaluated in a definitive trial before any
recommendations can be made. The pitfalls of colloi-
dal fluid resuscitation include allergic or febrile reac-
tions, effects on coagulation, and renal toxicity.
Albumin has the best safety profile but is in short sup-
ply and therefore expensive. Gelatins have a higher
incidence of allergic reaction but their effect on coagu-
lation, like human albumin solution, is largely
dilutional.46 Allergic and febrile reactions also occur
with dextrans.43 46 Higher molecular weight starches
might cause renal toxicity but only if given in large
doses.59 60 In the studieswe reviewed, synthetic colloids
did not result in renal toxicity, coagulation, or bleeding
problems,40 but bleeding problemshave been reported
in other clinical studies.61 Finally, none of these solu-
tions are routinely available in sub-Saharan African
countries and would require the results of a well pow-
ered trial and cost analysis to inform future policy.
Limitations
Themajor limitation was that we considered only pub-
lished studies, which could introduce reporting bias.
This was not evident from a visual inspection of the
funnel plot (not shown), which was symmetrical. Too
few studies included children with sepsis, and the
observed effect of colloids on mortality was limited to
trials in severemalaria, which were unblinded and had
a potential for bias because of limitations of study
design.25
Conclusions
Though this reviewhas some interesting findings, it did
not identify sufficient evidence to inform the preferen-
tial use of either colloids or crystalloids for treating
paediatric shock. As the reported trials were small
and dealt with diverse morbidities (dengue, sepsis,
and malaria) and thus did not approach the manage-
ment of shock in an integrated manner, their findings
would be difficult to generalise across the paediatric
population. Broad based trials are needed to compare
the efficacy of fluid expansion of colloids and crystal-
loids in children. Design of such trials, however, will
have to take into consideration the safety concerns of
certain colloids.
Contributors: SA and HL were responsible for the literature review and
initial synthesis of results. SA was responsible for the data analysis. KM
conceived the idea for the study and supervised literature review and
results summaries. All authors contributed to the writing of the paper and
approved the final draft. KM is guarantor.
Funding: This work was funded indirectly through programme support by
the Wellcome Trust and Medical Research Council. SA is supported by a
grant from the Wellcome Trust (No 084538). The Wellcome Trust had no
role in the review and in the preparation of this manuscript.
Competing interests: All authors have completed the Unified Competing
Interest form at www.icmje.org/coi_disclosure.pdf (available on request
from the corresponding author) and declare: no support from any
institution for the submitted work; no financial relationships with any
institutions that might have an interest in the submitted work in the
previous 3 years; no other relationships or activities that could appear to
have influenced the submitted work.
Ethical approval: Not required.
Data sharing: No additional data available.
1 Carcillo JA, Tasker RC. Fluid resuscitation of hypovolemic shock:
acute medicine’s great triumph for children. Intensive Care Med
2006;32:958-61.
2 Mecham N. Early recognition and treatment of shock in the pediatric
patient. J Trauma Nurs 2006;13:17-21.
3 Alderson P, Bunn F, Lefebvre C, Li WP, Li L, Roberts I, et al. Human
albumin solution for resuscitation and volume expansion in critically
ill patients. Cochrane Database Syst Rev 2002;1:CD001208.
4 Alderson P, Bunn F, Lefebvre C, Li WP, Li L, Roberts I, et al. Human
albumin solution for resuscitation and volume expansion in critically
ill patients. Cochrane Database Syst Rev 2004;4:CD001208.
5 Alderson P, Schierhout G, Roberts I, Bunn F. Colloids versus
crystalloids for fluid resuscitation in critically ill patients. Cochrane
Database Syst Rev 2000;2:CD000567.
6 Bunn F, Lefebvre C, Li Wan Po A, Li L, Roberts I, Schierhout G. Human
albumin solution for resuscitation and volume expansion in critically
ill patients. The Albumin Reviewers. Cochrane Database Syst Rev
2000;2:CD001208.
7 Bunn F, Trivedi D, Ashraf S. Colloid solutions for fluid resuscitation.
Cochrane Database Syst Rev 2008;1:CD001319.
8 Haynes GR, Navickis RJ, Wilkes MM. Albumin administration—what
is theevidence of clinical benefit? A systematic reviewof randomized
controlled trials. Eur J Anaesthesiol 2003;20;10:771-93.
9 Liberati A,Moja L,Moschetti I, Gensini GF, Gusinu R. Human albumin
solution for resuscitation and volume expansion in critically ill
patients. Intern Emerg Med 2006;1:243-5.
10 Vincent JL, Navickis RJ,WilkesMM.Morbidity in hospitalizedpatients
receivinghumanalbumin: ameta-analysis of randomized, controlled
trials. Crit Care Med 2004;32:2029-38.
11 Wilkes MM, Navickis RJ. Patient survival after human albumin
administration. Ameta-analysis of randomized, controlled trials.Ann
Intern Med 2001;135:149-64.
12 Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A
comparison of albumin and saline for fluid resuscitation in the
intensive care unit. N Engl J Med 2004;350:2247-56.
13 Brierley J, Peters MJ. Distinct hemodynamic patterns of septic shock
at presentation to pediatric intensive care. Pediatrics
2008;122:752-9.
14 McKiernan CA, Lieberman SA. Circulatory shock in children: an
overview. Pediatr Rev 2005;26:451-60.
15 Carcillo JA, Fields AI, American College of Critical Care Medicine Task
Force Committee M. Clinical practice parameters for hemodynamic
support of pediatric and neonatal patients in septic shock. Crit Care
Med 2002;30:1365-78.
16 Goldstein B, Giroir B, Randolph A. International pediatric sepsis
consensus conference: definitions for sepsis and organ dysfunction
in pediatrics. Pediatr Crit Care Med 2005;6:2-8.
WHAT IS ALREADY KNOW ON THIS TOPIC
There is no overall clear benefit for the use of colloids over crystalloids for volume
resuscitation in patients of all ages
Volume expansion with crystalloids results in better survival in patients with trauma,
gastroenteritis, burns, and traumatic brain injury
Volume expansion with human albumin solution or other colloids could be better than
crystalloids in specific groups of patients with sepsis from various causes
WHAT THIS STUDY ADDS
Compared with crystalloids, there is some weak evidence that volume expansion with
colloids could result in better survival in children with certain severe infections
Few studies have compared the survival benefit of colloids versus crystalloids in those with
sepsis, in whom colloids might be beneficial
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 7 of 8
17 World HealthOrganization. Pocket book of hospital care for children:
guidelines for the management of common illnesses with limited
resources. WHO, 2005.
18 Sparrow A, Hedderley T, Nadel S. Choice of fluid for resuscitation of
septic shock. Emerg Med J 2002;19:114-6.
19 World Health Organization. Management of the child with a serious
infection or severe malnutrition: guidelines for care at the first-
referral level in developing countries. WHO, 2000.
20 World Health Organization. Emergency triage assessment and
treatment (ETAT). Manual for participants. WHO, 2005.
21 Cole RP. The UK albumin debate. Burns 1999;25:565-8.
22 CfRaD. Undertaking systematic reviews of research on effectiveness:
CRD’s guidance for carrying out or commissioning reviews. 2nd ed.
University of York, 2001.
23 Haynes RB, McKibbon KA, Wilczynski NL, Walter SD, Werre SR.
Optimal search strategies for retrieving scientifically strong studiesof
treatment fromMedline: analytical survey. BMJ 2005;330:1179.
24 Review Manager (RevMan) [computer programme]. Version 5.0.
Nordic Cochrane Centre, Cochrane Collaboration, 2008.
25 Higgins JPT,GreenS, eds. Cochranehandbook for systematic reviews
of interventions. Version 5.0.2. Cochrane Collaboration, 2008.
26 Alpar EK, Killampalli VV. Effects of hypertonic dextran in
hypovolaemic shock: a prospective clinical trial. Injury
2004;35:500-6.
27 Beards SC, Watt T, Edwards JD, Nightingale P, Farragher EB.
Comparison of the hemodynamic and oxygen transport responses to
modified fluid gelatin and hetastarch in critically ill patients: a
prospective, randomized trial. Crit Care Med 1994;22:600-5.
28 Haibach L, Baubeau D, Jahn H. [Significance of a modified gelatin
polymer in the control of hypovolemia. Application to hemodialysis].
Anesth Analg (Paris) 1976;3:673-89.
29 Ochocka M. [Blood and blood derivatives in the treatment of infants
and older children. II]. Pediatr Pol 1984;59:873-80.
30 Pockaj BA, Yang JC, Lotze MT, Lange JR, Spencer WF, Steinberg SM,
et al. A prospective randomized trial evaluating colloid versus
crystalloid resuscitation in the treatment of the vascular leak
syndrome associated with interleukin-2 therapy. J Immunother
Emphasis Tumor Immunol 1994;15:22-8.
31 Rackow EC, Falk JL, Fein IA, Siegel JS, Packman MI, Haupt MT, et al.
Fluid resuscitation in circulatory shock: a comparison of the
cardiorespiratory effectsof albumin, hetastarch, andsaline solutions
in patients with hypovolemic and septic shock. Crit Care Med
1983;11:839-50.
32 Rahman O, Bennish ML, Alam AN, SalamMA. Rapid intravenous
rehydration by means of a single polyelectrolyte solution with or
without dextrose. J Pediatr 1988;113:654-60.
33 Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F,
Lemaire F, et al. Effects of hydroxyethylstarch and gelatin on renal
function in severe sepsis: a multicentre randomised study. Lancet
2001;357:911-6.
34 Tanaka R, Watanabe T. [Effect of lactated ringer solution with 2
percent gelatin on the circulatory and respiratory systems.]Masui
1975;24:873-9.
35 Veneman TF, Oude Nijhuis J, Woittiez AJ. Human albumin and starch
administration in critically ill patients: a prospective randomized
clinical trial.Wien Klin Wochenschr 2004;116:305-9.
36 Weis KH. [Haemaccel 35: adverse reactions in a multicentric,
prospective study.] Anaesthesist 1983;32:488-93.
37 Maitland K, Pamba A, Newton CR, Levin M. Response to volume
resuscitation in children with severe malaria. Pediatr Crit Care Med
2003;4:426-31.
38 Maitland K, Pamba A, English M, Peshu N, Marsh K, Newton C, et al.
Randomized trial of volume expansion with albumin or saline in
children with severe malaria: preliminary evidence of albumin
benefit. Clin Infect Dis 2005;40:538-45.
39 Maitland K, Pamba A, English M, Peshu N, Levin M, Marsh K, et al.
Pre-transfusion management of children with severe malarial
anaemia: a randomised controlled trial of intravascular volume
expansion. Br J Haematol 2005;128:393-400.
40 Akech S, Gwer S, Idro R, Fegan G, Eziefula AC, Newton CR, et al.
Volume expansion with albumin compared to gelofusine in children
with severe malaria: results of a controlled trial. PLoS Clin Trials
2006;1:e21.
41 Dung NM, Day NP, Tam DT, Loan HT, Chau HT, Minh LN, et al. Fluid
replacement in dengue shock syndrome: a randomized, double-
blind comparison of four intravenous-fluid regimens. Clin Infect Dis
1999;29:787-94.
42 NgoNT, CaoXT, KneenR,Wills B, NguyenVM,Nguyen TQ, et al. Acute
management of dengue shock syndrome: a randomized double-
blind comparison of 4 intravenous fluid regimens in the first hour.
Clin Infect Dis 2001;32:204-13.
43 Wills BA, Nguyen MD, Ha TL, Dong THT, Tran TNT, Le TTM, et al.
Comparisonof three fluid solutions for resuscitation indengue shock
syndrome. N Engl J Med 2005;353:877-89.
44 Cifra HL, Velasco JNJ. A comparative study of the efficacy of 6%Haes-
Steril and Ringer’s lactate in the management of dengue shock
syndrome 555. Crit Care Shock 2003;6:95-100.
45 Upadhyay M, Singhi S, Murlidharan J, Kaur N, Majumdar S.
Randomized evaluation of fluid resuscitationwith crystalloid (saline)
and colloid (polymer from degraded gelatin in saline) in pediatric
septic shock. Indian Pediatr 2005;42:223-31.
46 Roberts JS, Bratton SL. Colloid volume expanders. Problems, pitfalls
and possibilities. Drugs 1998;55:621-30.
47 Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation
in critically ill patients. Cochrane Database Syst Rev
2007;4:CD000567.
48 Roberts I, Alderson P, Bunn F, Chinnock P, Ker K, Schierhout G.
Colloids versus crystalloids for fluid resuscitation in critically ill
patients. Cochrane Database Syst Rev 2004;4:CD000567.
49 NguyenTH,NguyenTL, LeiH-Y, LinY-S, LeBL,HuangK-J, et al. Volume
replacement in infants with dengue hemorrhagic fever/dengue
shock syndrome. Am J Trop Med Hyg 2006;74:684-91.
50 Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality
and discrepancies between large and small randomized trials in
meta-analyses. Ann Intern Med 2001;135:982-9.
51 Kunz R, Vist G, Oxman AD. Randomisation to protect against
selection bias in healthcare trials. Cochrane Database Syst Rev
2007;2:MR000012.
52 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of
bias. Dimensions of methodological quality associated with
estimates of treatment effects in controlled trials. JAMA
1995;273:408-12.
53 Deeks JJ, Dinnes J, D’Amico R, SowdenAJ, SakarovitchC, Song F, et al.
Evaluating non-randomised intervention studies. Health Technol
Assess 2003;7:1-173.
54 Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al.
Early goal-directed therapy in the treatment of severe sepsis and
septic shock. N Engl J Med 2001;345:1368-77.
55 Carcillo JA, Davis AL, Zaritsky A. Role of early fluid resuscitation in
pediatric septic shock. JAMA 1991;266:1242-5.
56 Han YY, Carcillo JA, Dragotta MA, Bills DM, Watson RS,
Westerman ME, et al. Early reversal of pediatric-neonatal septic
shock by community physicians is associated with improved
outcome. Pediatrics 2003;112:793-9.
57 Vincent JL. Resuscitation using albumin in critically ill patients:
research in patients at high risk of complications is nowneeded.BMJ
2006;333:1029-30.
58 Wills BA, Oragui EE, Dung NM, Loan HT, Chau NV, Farrar JJ, et al. Size
and charge characteristics of the protein leak in dengue shock
syndrome. J Infect Dis 2004;190:810-8.
59 Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M,
Weiler N, et al. Intensive insulin therapy and pentastarch
resuscitation in severe sepsis. N Engl J Med 2008;358:125-39.
60 Wiedermann CJ. Systematic review of randomized clinical trials on
the use of hydroxyethyl starch for fluid management in sepsis. BMC
Emerg Med 2008;8:1.
61 De Jonge E, Levi M. Effects of different plasma substitutes on blood
coagulation: a comparative review. Crit Care Med 2001;29:1261-7.
Accepted: 28 June 2010
RESEARCH
page 8 of 8 BMJ | ONLINE FIRST | bmj.com
